A Randomized Controlled, Trial of the GLP-1 Receptor Agonist Exenatide in Idiopathic Intracranial Hypertension
Creator
James Mitchell, Major RAMC
Affiliation
University of Birmingham, England
Subject
Pseudotumor Cerebri; High Intracranial Pressure/Headache
Description
Pre-clinical data demonstrates the ability of Exenatide, a GLP-1R agonist, to reduce CSF secretion and ICP.1 Existing GLP- 1R agonists are widely used to treat obesity and diabetes (but do not cause hypoglycaemia).
Date
2022-02
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2022 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS Annual Meeting 2022: Scientific Platform Session II